JATT III Acquisition Corp Ordinary Shares

JATT III Acquisition Corp Ordinary Shares(JTTT)の株式分析

$10.300

0.000 (0.00%)終値時点

Loading chart…
高値
10.320
始値
10.250
出来高加重平均価格
10.28
出来高
5.85K
時価総額
—
安値
10.213
売買代金
60.10K
EV/EBITDA(TTM)
0.00

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

AI分析 of JATT III Acquisition Corp Ordinary Shares (JTTT)

中立

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

バリュエーション指標

JATT III Acquisition Corp Ordinary Shares(JTTT)の現在の予想PERは0.00で、5年平均はです。

予想PER

5年平均 P/E
現在のP/E
0.00

予想EV/EBITDA

5年平均 EV/EBITDA
現在のEV/EBITDA
0.00

予想PSR

5年平均 P/S
現在のP/S
0.00

イベントタイムライン

2026-09-21 (ET)

16:00:00

Nscale Limited Files for IPO, Plans to List on NYSE

JTTT のよくある質問 — Alphio AI が回答

JATT III Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The Company has not selected any business combination target, and the Company has not initiated any substantive discussions, directly or indirectly, with any business combination target. The Company intends to focus its search on healthcare and healthcare-related businesses, with a primary emphasis on biotechnology and broader life sciences. The Company is not engaged in any business operations and has not generated any revenue.

JTTT is not a strong buy right now due to its low RSI of 37.401, indicating potential oversold conditions, and a current price of 10.30, which is close to its 52-week low of 10.00. The stock has shown a 20-day change of -4.63%, suggesting a downward trend. However, the projected final change of +1047.66% based on historical patterns indicates potential for significant upside in the long term. The main risk is its current ratio of 0.28, indicating liquidity concerns.

コミュニティ

もっと見る ↗

投稿はまだありません

登録またはログインして議論に参加

関連記事

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める